Is enzalutamide/enzalutamide effective for all men with prostate cancer?

Enzalutamide/enzalutamide, an oral androgen receptor antagonist, can be used to treat patients with metastatic castration-resistant prostate cancer who have been treated with other drugs. It does not work by reducing androgen levels, but through a novel mechanism of action that inhibits three key links in the androgen receptor signaling pathway.

However, a common misconception is that enzalutamide produces significant benefits in all men with prostate cancer. In fact, its efficacy is affected by many factors, including individual patient differences, specific molecular markers of the cancer, and the stage of the disease. Clinical studies have shown that enzalutamide has a certain therapeutic effect in the treatment of metastatic hormone-sensitive and hormone-resistant prostate cancer.

In the treatment of metastatic hormone-sensitive prostate cancer, enzalutamide combined with other treatments, especially hormone therapy, can significantly prolong the patient's survival and slow down the spread of cancer cells, thereby effectively improving the patient's quality of life. For prostate cancer patients who have become resistant to hormone therapy, enzalutamide can be used as the treatment of choice.

Enzalutamide has a unique mode of action. It can effectively block the binding of androgens to their receptors through competitive inhibition, further inhibit the nuclear translocation of androgen receptors, and interfere with the interaction betweenDNA and androgen receptors. Enzalutamide displays greater affinity for the androgen receptor than conventional drugs such as bicalutamide without producing unwanted agonist activity.

In addition, using enzalutamide may be associated with side effects such as fatigue, dizziness, or high blood pressure. Therefore, before starting treatment, doctors need to fully evaluate the patient's overall health and the possible risks of using this drug.